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CORRESPONDENCE
Letters to the Editor
Trials and Tribulations of Noninferiority:
The Ximelagatran Experience
The review of noninferiority trial design in the November 8 issue of
JACC (1) takes a critical view of the SPORTIF III and V trials, which
compared ximelagatran to warfarin in patients with atrial fibrillation.
Kaul et al. (1) confuse statistical issues with pharmacological limita-
tions of ximelagatran and problems associated with double-blind
versus open-trial design. In many ways, the study traces the arguments
in the U.S. Food and Drug Administration statistical review leading
to rejection of the ximelagatran marketing application by the agency
last year. We take issue with several points:
1. The noninferiority margin reflects an estimate of the propor-
tion of warfarin efficacy that might be lost in exchange for certain
therapeutic advantages. There is more focus on the predefined
delta than on the results, which were consistent with noninferi-
ority for margins down to 0.13%/year for SPORTIF III, 1.03%/
year for SPORTIF V, and 0.44%/year for the prespecified pooled
analysis of primary outcomes. Selection of the 2% margin was
based on an expected warfarin event rate of 3.1%/year and
judgment about the difference that would be clinically mean-
ingful (2). The observed rates on warfarin were lower, as were
the upper limits of 95% confidence.
2. The investigators (1) regard the expected warfarin rate as unreal-
istic, though it was based on previous trials adjusted for risk
factors (3). Warfarin efficacy is not homogeneous in absolute
terms for secondary prevention. Patients with prior thromboem-
bolism comprised 21% of the cohort of the 6 previous studies of
warfarin, including the European Atrial Fibrillation Trial (4); the
SPORTIF trials had the same proportion. An inherent weakness
of historical assessment of warfarin efficacy is that the only
previous double-blind trial included no women (5).
3. Kaul et al. (1) acknowledge that retention of 50% of warfarin
efficacy as a prerequisite for noninferiority is arbitrary. To pre-
serve this level of efficacy, the relative delta in the SPORTIF
trials would have been 1.471. Kaul et al. (1) divide the assumed
warfarin event rate by the absolute margin to arrive at a relative
margin of 1.65. Calculated conservatively from meta-analyses
of earlier studies, the relative delta would be about 1.4.
Although the noninferiority criteria applied to the SPORTIF
trials compared absolute differences, relative rate ratios for
ximelagatran/warfarin (95% CI) follow:
• SPORTIF III 0.713 (0.477, 1.065)
• SPORTIF V 1.390 (0.913, 2.116)
• Pooled analyses 0.982 (0.737, 1.308)
The results of SPORTIF III and pooled analyses meet the
relative margin criterion of 1.4. As with any reasonable relative
margin, however, SPORTIF V was inconclusive.
4. Neglecting SPORTIF III and the pooled results overlooks not
only the hard end points, blinded evaluations, and exhaustive
measures to minimize bias, but also neglects the generalizabil-
ity of observations to clinical practice. Although noninferiority
can be questioned for SPORTIF V, ximelagatran was unde-
niably noninferior in both SPORTIF III and in the pooled
results according to even the most conservative assessment.
5. Kaul et al. (1) consider noninferior efficacy for stroke prevention
undermined by liver toxicity. While potentially deleterious effects
must be considered in balancing risks and benefits, this goes
beyond the noninferiority assessment for efficacy in the primary
analysis.
Over a span of 11,346 patient-years (mean 18.5 months/patient) in
the SPORTIF trials, primary events occurred in 93 patients given
warfarin and 91 given ximelagatran: rates of 1.65%/year and
1.62%/year, respectively (difference 0.03; 95% CI 0.50 to
0.44%/year, p  0.94). Even with careful warfarin adjustment,
ximelagatran caused less bleeding. The trials were not designed to
evaluate the potential for ximelagatran to cause hepatotoxicity, and
developing ways to manage that risk requires additional research.
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